Key Highlights
- BCAL Diagnostics (ASX:BDX) completed clinical validation of BREASTESTplus 2 and targeted a November 2026 launch, subject to preparations.
- Avantect Multicancer became available in selected Sydney and Melbourne locations.
- Quarterly Revenue was AUD 30,800, and BCAL held AUD 580,000 in cash at the end of September.
- The company increased its stake in Genetic Signatures to approximately 18.46%.
BCAL Diagnostics (ASX:BDX), an Australian company developing and offering blood-based cancer detection tests, reported validation and rollout milestones in its September 2026 quarterly filing. The 30 October update described preparations for a new version of its breast test, the limited release of a multicancer test and steps to broaden access. It also provided figures for test volumes, cash use and convertible note funding.
Breast test validation and launch preparations
BCAL completed clinical validation of BREASTESTplus 2 in women aged 30 and above across all breast densities. In that validation study, the company reported 80.3% sensitivity and 48.5% specificity for early-stage breast cancer. That study grouping comprised stage 0 ductal carcinoma in situ and stages 1 and 2. BCAL described the test as a source of additional information alongside imaging and other clinical pathways. The company said it is designed to supplement existing clinical pathways and mammography remains part of routine care.
The company targeted a November 2026 launch in Sydney, Melbourne and Brisbane, subject to completing accreditation and operational preparations. It planned broader national availability after that initial rollout. BCAL said women who access the test through participating sites would be offered a chance to join a registry intended to collect real-world evidence.
Initial multicancer rollout
BCAL introduced Avantect Multicancer in selected Sydney and Melbourne locations and was preparing for a broader rollout with Sonic Healthcare and Healius. The test looks for signals associated with eight cancer types and provides a likely organ-of-origin signal when it detects one. Samples were initially analysed at ClearNote Health’s US laboratory.
In ClearNote’s case-control validation study, the test showed 56.2% overall sensitivity and 98.4% specificity across the cancers and stages included in the analysis. The filing said a result with no detected signal cannot rule out cancer and described Avantect as complementary to established screening and clinically recommended investigations. BCAL also updated online referral pathways and education materials for clinicians and patients.
Revenue, funding and the Genetic Signatures stake
BCAL reported 29 tests in the quarter across Avantect Pancreatic and BREASTESTplus. Net operating cash outflow was AUD 1.895 million, including AUD 1.236 million of Research and Development costs. After quarter-end, the company received an AUD 2.237 million research and development tax offset and reported repayment of an AUD 1.397 million loan.
BCAL drew a further AUD 2.5 million under its AUD 10 million convertible note Facility during the quarter. The principal drawn reached AUD 7.6 million at 30 September. Shareholders approved access to the AUD 2.4 million remainder on 19 October. BCAL also bought another 18.75 million Genetic Signatures shares for AUD 1.5 million at eight Australian cents per share, taking its holding to 41,923,644 shares.
Commercial and research priorities
BCAL’s next commercial steps included completing accreditation and operational work for the targeted breast test launch and extending access to Avantect Multicancer. The company received ethics approval to expand an existing breast cancer research programme to collect and analyse samples for multiomic assay development. It also planned continued clinician engagement and further work on scientific publications supporting its diagnostic research. In October, BCAL presented work supporting development and validation of its breast test at a lipid research conference in Perth. It also convened a clinical advisory panel with 10 breast specialists in Brisbane. In the September quarter, the company supported a clinician education event on early detection of gastrointestinal disorders that drew more than 130 general practitioners in person and online.






Please wait processing your request...